Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Christine NitschkeBenedikt MarkmannPhilipp WalterAnita BadbaranMarie TölleJolanthe KropidlowskiYassine BelloumMara R GoetzJan BardenhagenLouisa SternJoseph TintelnotMartin SchönleinMarianne SinnPaul van der LeestRonald SimonAsmus HeumannJakob R IzbickiKlaus PantelHarriett WikmanFaik G UzunogluPublished in: Clinical chemistry (2023)
KRAS ctDNA detection is an independent adverse prognostic marker in curative and palliative PDAC patients-at all sites of blood draw and a strong follow-up marker. The most substantial prognostic impact was seen for PV blood, which could be an effective novel tool for identifying prognostic borderline patients-guiding future decision-making on neoadjuvant treatment despite anatomical resectability. In addition, higher PV mutant copy numbers contribute to an improved technical feasibility.
Keyphrases
- end stage renal disease
- wild type
- decision making
- prognostic factors
- rectal cancer
- newly diagnosed
- chronic kidney disease
- ejection fraction
- loop mediated isothermal amplification
- palliative care
- lymph node
- label free
- peritoneal dialysis
- circulating tumor
- emergency department
- current status
- squamous cell carcinoma
- patient reported outcomes
- radiation therapy
- combination therapy
- patient reported
- free survival
- advanced cancer
- chemotherapy induced